<DOC>
	<DOCNO>NCT01336647</DOCNO>
	<brief_summary>Phase 2 study ass safety effectiveness product treat child adult head louse</brief_summary>
	<brief_title>An Efficacy Safety Study Ha44 Gel Administered Topically Treatment Head Lice Infestation</brief_title>
	<detailed_description />
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Lice Infestations</mesh_term>
	<criteria>2 year age old Body weight least 33 pound Has active head lice infestation Day 0 . An active infection define least 3 live louse index subject least 1 live louse household member Belong household 6 member , except additional household member &lt; 2 year age Belong household eligible index subject 2 12 year age active louse infestation Female subject must : nonchildbearing potential ( history menstrual period , posthysterectomy , , postmenopausal least 2 year ) OR , childbearing potential , must negative urine pregnancy test prior treatment agree use highly effective method contraception Day 0 Day 14 visit . Had treatment head louse within 14 day prior Day 0 Has household member ( ) infest louse willing eligible enrollment Has condition illness , opinion Investigator , may interfere study result Has electrocardiographic abnormality , renal disease impair renal function , dermatological disease face , scalp , ears neck , active ophthalmological disease , moderate severe scleral injection conjunctival erythema purulent discharge allergic perennial rhinitis require chronic treatment Has use hormonal contraception le 3 month pregnant lactating Has receive systemic corticosteroid within 7 day prior Day 0 plan study Receiving systemic topical medication , opinion Investigator , may interfere study result Has receive investigational agent within 30 day prior Day 0</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>